Transdermal Patch Medication Delivery Systems and Pediatric Poisonings,2002-2006

Abstract

Transdermal drug delivery systems are an increasingly popular method of medication delivery containing large quantities of medication and presenting new opportunities for toxicity. To provide a description of exposures to transdermal medications in a pediatric population, we studied exposures in individuals less than 12 years of age. This is a retrospective database study in which the Texas Poison Center Network database from 2002 to 2006 was reviewed. In all, 336 poison control center records of patch exposures over the 5-year period were identified. Of those, 110 cases involved children less than 12 years old. A majority of cases resulted in no significant clinical effects. One death resulted from opioid toxicity. Although a majority of patch exposures in children less than 12 years of age resulted in no significant clinical toxicity, practitioners and the public must be made aware of the available patch-based medications and their potential for toxicity in children.

Keywords

poisoning pediatric patch transdermal

Get full access to this article

View all access options for this article.

References

Schneider NG , Koury MA , Cortner C. , et al. Preferences among four combination nicotine treatments [published online ahead of print August 1, 2006]. Psychopharmacology (Berl). 2006;187:476-485.

Winblad B. , Kawata AK , Beusterien KM , et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry. 2007;22:485-491.

Priano L. , Gasco MR , Mauro A. Transdermal treatment options for neurological disorders: impact on the elderly [Review]. Drugs Aging. 2006;23:357-375.

Alternative routes of drug administration-advantages and disadvantages (subject review). American Academy of Pediatrics. Committee on Drugs. Pediatrics. 1997; 100:143-152.

Nitti VW , Sanders S. , Staskin DR , et al. Transdermal delivery of drugs for urologic applications: Basic principles and applications. Urology. 2006 ;4:657-664.

Dixit N. , Bali V. , Baboota S. , Ahuja A. , Ali J. Iontophoresis: an approach for controlled drug delivery: a review. Curr Drug Deliv. 2007;4:1-10.

Karande P. , Jain A. , Mitragotri S. Discovery of transdermal penetration enhancers by high-throughput screening . Nat Biotechnol. 2004;22:192-197.

Wilkosz MF , Bogner RH Transdermal drug delivery. Part 1: Current status. US Pharm . 2003;28:4. http:// www.uspharmacist.com/index.asp?show=article_page=8_ 1061.htm. Accessed August 30, 2007.

Carter KA Heat-associated increase in transdermal fentanyl absorption. Am J Health Syst Pharm. 2003;60: 191-192.

10.

Watson WA , Litovitz TL , Klein-Schwartz W. , et al. 2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med . 2004;22:335-404.

11.

Schneiders W. , Rollow A. , Rammelt S. , et al. Risk-inducing activities leading to injuries in a child and adolescent population of Germany. J Trauma. 2007;62:996-1003.

12.

Lee M. , Phillips J.

FDA safety page. Transdermal patches: high risk for error?

Drug Topics. 2002;1:54-55. htpp://www.fda.gov/cder/drug/MedErrors/transdermal.pdf. Accessed August 12, 2007.

13.

Schneiders W. , Rollow A. , Rammelt S. , et al. Risk-inducing activities leading to injuries in a child and adolescent population of Germany. J Trauma. 2007;62:996-1003.

14.

Agran PF , Winn D. , Anderson C. , Trent R. , Walton-Haynes L. Rates of pediatric and adolescent injuries by year of age. Pediatrics. 2001;108:E45.

15.

Akcan R. , Hilal A. , Gulmen MK , Cekin N. Childhood deaths due to electrocution in Adana, Turkey. Acta Paediatr. 2007;96:443-445.

16.

FDA Drug Advisory. http://www.fda.gov/cder/drug/advisory/fentanyl.html. Accessed November 25, 2007.

17.

Agran PF , Anderson C. , Winn D. , Trent R. , Walton-Haynes L. , Thayer S. Rates of pediatric injuries by 3-month intervals for children 0 to 3 years of age. Pediatrics. 2003;111:e683-692.

18.

Lopez FA ADHD: new pharmacological treatments on the horizon. J Dev Behav Pediatr. 2006;27:410-416.

19.

Barrett SP , Darredeau C. , Bordy LE , Pihl RO Characteristics of methylphenidate misuse in a university student sample. Can J Psychiatry. 2005;50: 457-461.

20.

Poulin C. From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots. Addiction. 2007;102:740-751.

21.

Haroz R. , Greenberg MI New drugs of abuse in North America. Clin Chem Lab Med. 2006;26:147-164.